PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has PYC Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: PYC's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: PYC exceeded the Australian Biotechs industry which returned -10.9% over the past year.
Return vs Market: PYC exceeded the Australian Market which returned 35.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is PYC Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StHere's What PYC Therapeutics Limited's (ASX:PYC) Shareholder Ownership Structure Looks Like
1 month ago | Simply Wall StWe're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
2 months ago | Simply Wall StNon-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Is PYC Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PYC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PYC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PYC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: PYC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PYC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PYC is overvalued based on its PB Ratio (8x) compared to the AU Biotechs industry average (4.9x).
How is PYC Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PYC Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has PYC Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PYC is currently unprofitable.
Growing Profit Margin: PYC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PYC is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare PYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: PYC has a negative Return on Equity (-20.59%), as it is currently unprofitable.
How is PYC Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PYC's short term assets (A$57.4M) exceed its short term liabilities (A$1.2M).
Long Term Liabilities: PYC's short term assets (A$57.4M) exceed its long term liabilities (A$600.5K).
Debt to Equity History and Analysis
Debt Level: PYC is debt free.
Reducing Debt: PYC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PYC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PYC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 19% each year
What is PYC Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PYC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PYC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PYC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PYC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PYC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rohan Hockings (37 yo)
Dr. Rohan Hockings, MBBS (Hons.), J.D., G.D.L.P, has been Chief Executive Officer at PYC Therapeutics Limited since August 2020. He served as Chief Strategy Officer at PYC Therapeutics Limited until August...
CEO Compensation Analysis
Compensation vs Market: Rohan's total compensation ($USD335.91K) is below average for companies of similar size in the Australian market ($USD713.55K).
Compensation vs Earnings: Rohan's compensation has been consistent with company performance over the past year.
Experienced Management: PYC's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: PYC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PYC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.2%.
PYC Therapeutics Limited's company bio, employee growth, exchange listings and data sources
- Name: PYC Therapeutics Limited
- Ticker: PYC
- Exchange: ASX
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$507.348m
- Shares outstanding: 3.17b
- Website: https://pyctx.com
- PYC Therapeutics Limited
- Harry Perkins Institute of Medical Resea
- 6 Verdun Street
- Western Australia
PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-pe...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 08:21|
|End of Day Share Price||2021/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.